好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Influence of Age of Onset on Huntington’s Disease Phenotype
Movement Disorders
S11 - Huntington's Disease, Tardive Dyskinesia, and Functional Movement Disorders (3:54 PM-4:06 PM)
003

To use a large database to determine the difference in symptom profiles and disease progression between patients with early, typical, and late onset adult HD at different stages of disease.

There is suggestion that older patients with Huntington’s disease (HD) have a milder disease course with less behavioral symptoms than younger HD patients. However, phenotypic differences based on age of onset have not been well characterized in a large HD population. 

Data were obtained from Enroll-HD. Adults with manifest HD were included. Age groups were defined as young onset (20-29 years), typical onset (30-50 years), and late onset (51+ years). Subjects in each group were categorized by TFC total score bins, from Stage I (least severe) to Stage V (most severe). Motor, cognitive, and behavioral symptoms were analyzed. We calculated descriptive statistics and Bonferroni p-value correction for pairwise comparison.

7,311 manifest HD subjects were included (612 young onset, 4,189 typical onset, and 2,510 late onset). The rate of decline in TFC score from baseline to second visit was significantly faster for young onset (-1.79 points) compared to the typical (-1.21, p<0.05) or late onset (-1.15, p<0.05) participants. Motor deficits were worse for late onset participants at early stages of HD, and worse for young onset participants at late stages. Young onset participants had a greater burden of behavioral symptoms at early and moderate stages of disease.

Younger age of onset is predictive of a faster functional decline for adults with HD when compared to those with typical and late age of onset. Motor and behavioral symptom profiles differ based on age of onset.

Authors/Disclosures

PRESENTER
No disclosure on file
Danielle Larson, MD (Northwestern University, Feinberg School of Medicine) Dr. Larson has received personal compensation in the range of $0-$499 for serving as a Consultant for Acadia Pharmaceuticals.
No disclosure on file
Danny Bega, MD (Northwestern University) Dr. Bega has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GE Healthcare. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as a Consultant for WebMD. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Acorda Therapeutics. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine Biosciences. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Supernus Pharmaceuticals. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sunovion. Dr. Bega has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ACTN / ANA. The institution of Dr. Bega has received research support from Huntington Disease Society of America. The institution of Dr. Bega has received research support from Parkinson Foundation.